ATRC: Revenue grew 15% as profitability expanded, despite pressure from PFA adoption

What happened

Atricure reported Q3 revenue of $154.5 million, up 15% year over year, net income of $4.1 million, and adjusted EBITDA, a measure of operating earnings, up 51% to $26.8 million. It guided to fiscal 2026 revenue of about $606 million to $610 million and said PFA adoption pressured minimally invasive ablation.

Confirmed

Global impact / market context

Revenue and adjusted EBITDA grew, but the stated pressure from PFA adoption points to a challenge in minimally invasive ablation. If that pressure limits sales, it could make the fiscal 2026 revenue range harder to achieve; continued growth could help support earnings.

Analyst inference

The article gives a revenue outlook alongside strong reported quarterly growth, but also identifies a product-area pressure. For investors, the tension is whether growth across the business can offset weaker demand or competition affecting minimally invasive ablation, without assuming an unreported market reaction.

Analyst inference

What to watch

1. Future revenue reports can show whether Atricure’s sales remain consistent with its fiscal 2026 guidance of about $606 million to $610 million. Analyst inference
2. Updates on PFA adoption and minimally invasive ablation could clarify whether the reported pressure is easing or continuing to constrain sales. Analyst inference
3. Track net income and adjusted EBITDA in later results to see whether reported quarterly profitability growth continues alongside revenue growth. Analyst inference

Evidence

• Original source link unavailable